Isabelle Ray-Coquard
Centre Leon Berard · isabelle.ray-coquard@lyon.unicancer.fr · Centre Léon Bérard, Lyon, France
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Isabelle Ray-Coquard as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 16:29 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07763496 · Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical CancerARCAGY/ GINECO GROUP · not yet recruiting · Recurrent or Metastatic Cervical Cancer · study chair
- Ph2NCT05548296 · A Phase 2 Study of ACR-368 in Endometrial AdenocarcinomaAcrivon Therapeutics · recruiting · Endometrial Adenocarcinoma · principal investigator
- N/ANCT04256213 · COL Immunotherapy Before Radiochimio + IpilimumabARCAGY/ GINECO GROUP · completed · Cervix Cancer · principal investigator
- Ph2NCT03624244 · Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)Centre Leon Berard · recruiting · Low Grade Endometrial Stromal Sarcoma · principal investigator
- Ph2NCT03275506 · PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer .ARCAGY/ GINECO GROUP · completed · Ovarian Cancer Stage IV · principal investigator
- N/ANCT02981901 · Optimisation of Disease Management in Patients With Epithelial Ovarian Cancer in FranceCentre Leon Berard · unknown · Ovarian Epithelial Cancer · principal investigator
- Ph3NCT02477644 · Platine, Avastin and OLAparib in 1st LineArcagy Research · completed · Ovarian Cancer
- Ph2NCT01979393 · IRCI Gynae Sarcomas, High Grade Uterine SarcomaEuropean Organisation for Research and Treatment of Cancer - EORTC · completed · Uterine Sarcoma · study chair
- Ph2NCT01770301 · Efficacy and Safety of Bevacizumab (Avastin®) Combined to Weekly Paclitaxel Followed by Bevacizumab (Avastin®) Alone in Patients With Relapsed Ovarian Sex-cord Stromal Tumours (ALIENOR)ARCAGY/ GINECO GROUP · completed · Ovarian Sex-cord Stromal Tumor · principal investigator
- Ph2NCT01397877 · GINECO-EN102b - BKM120 as Monotherapy in the Treatment of Initial or Recurrent Metastatic Endometrial CancerARCAGY/ GINECO GROUP · completed · Endometrial Cancer · principal investigator
- N/ANCT01304043 · French Observatory of Rare Malignant Tumors of the OvaryARCAGY/ GINECO GROUP · completed · Ovarian Tumors · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 16:29 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 16:29 UTC. The ranking covers the 200 most relevant of 169 PubMed records, and a shared surname and initials can bring in a namesake. All 169 on PubMed
- Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.N Engl J Med · 20191,662 citationsRCR 62.5
- 1,432 citationsRCR 46.8
- Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.J Clin Oncol · 20141,311 citationsRCR 39.3
- 1,263 citationsRCR 32.1
- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.Lancet Oncol · 2017974 citationsRCR 29.9
- Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.N Engl J Med · 2022818 citationsRCR 55.4
- 566 citationsRCR 14.1
- 563 citationsRCR 13.5
- Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.J Clin Oncol · 2008504 citationsRCR 12.9
- BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.Cancer Discov · 2019384 citationsRCR 13.0